Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Клиническая эффективность амлодипина у больных с сердечно-сосудистыми заболеваниями
Ялымов А.А., Щикота А.М., Шехян Г.Г., Тимофеева Н.Ю., Задионченко В.С. Клиническая эффективность амлодипина у больных с сердечно-сосудистыми заболеваниями. Consilium Medicum. 2013; 15 (5): 70–76.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Задионченко В.С., Шехян Г.Г., Тимофеева Н.Ю. и др. Амлодипин: лидер врачебных рекомендаций в терапии сердечно-сосудистых заболеваний. Рус. мед. журн. 2011; 19 (4), (398): 217–22.
2. Sethi KK et al. Amlodipine monotherapy in mild to moderate hypertension. Indian Heart J 1994; 46 (1): 17–20.
3. Broadhurst P et al. Intra-arterial monitoring of the antihypertensive effects of once-daily amlodipine. J Hum Hypertens 1992; 6 (Suppl. 1): 9–12.
4. Horwitz LD et al. Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension. Am J Hypertens 1997; 10 (11): 1263–9.
5. Habeler G et al. Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of long-term study with a new calcium antagonist. Wien Klin Wochenschr 1992; 104 (1): 16–20.
6. Khokhani RC et al. Amlodipine in mild and moderate hypertension: initial Indian experiment. J Assoc Phisicians India 1993; 41 (10): 662–3.
7. Leenen FH et al. Persistence of antihypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. British J Clin Pharmacol 1996; 41 (2): 83–8.
8. Lichtlen PR, Fisher LD. Analysis of arrhythmias in the Circadian Antiischemia Program in Europe (CAPE) study. J Cardiovasc Pharmacol 1999; 33 (1): 135–9.
9. Susaguri M et al. Amlodipine lowers blood pressure without increasing sympathetic activity or activating the rennin-angiotensin system in patients with essential hypertension. Eur J Clin Pharmacol 1997; 53 (3–4): 197–201.
10. Hall RJ. A multicentral study comparing the efficacy and tolerability of nisoldipine coat-core and amlodipine in patients with chronic stable angina. Current Ther Res Clin Exp 1998; 59 (7): 483–97.
11. Pitt B et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503–10.
12. Detry JM. Amlodipine and the total ischemic burden: Circadian Anti-Ischemia Program in Europe (CAPE) trial – Methodology, safety and toleration. Cardiology 1994; 85 (Suppl. 2): 24–30.
13. Deanfield JE et al. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24 (6): 1460–7.
14. Kloner RA et al. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J Cardiol 1998; 81 (2): 163–9.
15. Lorimer AR et al. A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group. J Hum Hypertens 1989; 3 (3): 191–6.
16. Бубнова М.Г. Амлодипин в лечении сердечно-сосудистой патологии: доказанные антигипертензивный и антиатеросклеротический эффекты. Cons. Med. 2011; 10: 92–4.
17. Журавлева М.В., Черных Т.В., Алеева Г.Н. Особенности клинической эффективности и безопасности блокаторов кальциевых каналов. Справ. поликлин. врача. 2005; 2: 28–9.
18. Lau CP et al. Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. J Сardovasc Pharmacol 1996; 28 (2): 328.
19. Ajayi AA et al. The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension. J Natl Med Assoc 1995; 87 (7): 485–8.
20. Frishman WH et al. Amlodipine versus atenolol in essential hypertension. Am J Cardiol 1994; 73 (3): 50–4.
2. Sethi KK et al. Amlodipine monotherapy in mild to moderate hypertension. Indian Heart J 1994; 46 (1): 17–20.
3. Broadhurst P et al. Intra-arterial monitoring of the antihypertensive effects of once-daily amlodipine. J Hum Hypertens 1992; 6 (Suppl. 1): 9–12.
4. Horwitz LD et al. Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension. Am J Hypertens 1997; 10 (11): 1263–9.
5. Habeler G et al. Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of long-term study with a new calcium antagonist. Wien Klin Wochenschr 1992; 104 (1): 16–20.
6. Khokhani RC et al. Amlodipine in mild and moderate hypertension: initial Indian experiment. J Assoc Phisicians India 1993; 41 (10): 662–3.
7. Leenen FH et al. Persistence of antihypertensive effect after missed doses of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life. British J Clin Pharmacol 1996; 41 (2): 83–8.
8. Lichtlen PR, Fisher LD. Analysis of arrhythmias in the Circadian Antiischemia Program in Europe (CAPE) study. J Cardiovasc Pharmacol 1999; 33 (1): 135–9.
9. Susaguri M et al. Amlodipine lowers blood pressure without increasing sympathetic activity or activating the rennin-angiotensin system in patients with essential hypertension. Eur J Clin Pharmacol 1997; 53 (3–4): 197–201.
10. Hall RJ. A multicentral study comparing the efficacy and tolerability of nisoldipine coat-core and amlodipine in patients with chronic stable angina. Current Ther Res Clin Exp 1998; 59 (7): 483–97.
11. Pitt B et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503–10.
12. Detry JM. Amlodipine and the total ischemic burden: Circadian Anti-Ischemia Program in Europe (CAPE) trial – Methodology, safety and toleration. Cardiology 1994; 85 (Suppl. 2): 24–30.
13. Deanfield JE et al. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol 1994; 24 (6): 1460–7.
14. Kloner RA et al. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. Am J Cardiol 1998; 81 (2): 163–9.
15. Lorimer AR et al. A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group. J Hum Hypertens 1989; 3 (3): 191–6.
16. Бубнова М.Г. Амлодипин в лечении сердечно-сосудистой патологии: доказанные антигипертензивный и антиатеросклеротический эффекты. Cons. Med. 2011; 10: 92–4.
17. Журавлева М.В., Черных Т.В., Алеева Г.Н. Особенности клинической эффективности и безопасности блокаторов кальциевых каналов. Справ. поликлин. врача. 2005; 2: 28–9.
18. Lau CP et al. Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. J Сardovasc Pharmacol 1996; 28 (2): 328.
19. Ajayi AA et al. The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension. J Natl Med Assoc 1995; 87 (7): 485–8.
20. Frishman WH et al. Amlodipine versus atenolol in essential hypertension. Am J Cardiol 1994; 73 (3): 50–4.
Авторы
А.А.Ялымов, А.М.Щикота, Г.Г.Шехян, Н.Ю.Тимофеева, В.С.Задионченко
ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ
ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.